Form 4: Director Joseph Loscalzo Executes Stock Options at Ionis

Ionis Pharmaceuticals Director Joseph Loscalzo exercised stock options and sold 77,289 shares under a Rule 10b5-1 trading plan.

Summary

• Director Joseph Loscalzo exercised options for 77,289 shares of Ionis Pharmaceuticals common stock on May 4, 2026.
• The exercise prices for these options ranged from $38.06 to $64.80 per share.
• Following the exercise, the director sold the acquired shares in two tranches at weighted average prices of $74.90 and $75.58 per share.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent standard personal financial management by a director.

Positives

• The director demonstrated long-term commitment by holding various option tranches until their respective exercise dates.
• The transactions were conducted through a pre-arranged Rule 10b5-1 plan, which is a standard mechanism for orderly divestment.

Negatives

• The director reduced his direct beneficial ownership of Ionis Pharmaceuticals common stock from 113,619 shares to 36,330 shares following the sales.

Risks

• The reduction in equity ownership by a member of the Board of Directors may be perceived by some market participants as a decrease in alignment with long-term shareholder interests.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via Rule 10b5-1 plans is a common practice among biotech executives and directors to manage personal liquidity and diversify portfolios, and it generally does not signal a lack of confidence in the company's clinical or commercial pipeline.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to avoid potential conflicts of interest or accusations of trading on material non-public information.
• The scale of the divestment is consistent with typical director equity management practices in the mid-cap biotechnology sector.

Stakeholder Impact

• Shareholders should note the reduction in the director's direct equity stake, though the use of a 10b5-1 plan mitigates concerns regarding market timing.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Insider Trading, Form 4, Stock Options, Biotech, Director Transactions